Navigation Links
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Date:5/13/2008

V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies.

Everolimus is licensed to Abbott by Novartis for use on its drug eluting stents.

For images of Abbott's XIENCE V stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

*Event rates are based on Kaplan-Meier estimates; p-val
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
2. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
6. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
7. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
8. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009).../PRNewswire/--ZargisMedicalCorp.,asubsidiaryofSpee...orateResearch(NYSE: SI ),todayannouncedthatitsZarg...pisodeofCBS, TheEarlyShow duringasegmentinwhichMar...edfivewinningproductsfromthepublication,s2009"Best...viewedtelevisionmorningnewstalkshowbroadcastbyCBSf...
(Date:11/24/2009)...swire/--AmbitBiosciencesCorporationannouncedtodayt...,anovelsecondgenerationFLT3inhibitor,inAMLatthe51s...heldinNewOrleans,LA,December5-8,2009.Anoralpresent...eImonotherapysafetystudyinadultswithacutemyeloidle...sentedevaluatingtheeffectofAC220monotherapyandinco...
(Date:11/24/2009).../PRNewswire-FirstCall/--EchoTherapeutics,Inc.(OTCB...eSymphony(TM)tCGMSystemasanon-invasive,wireless,tr...ditsPrelude(TM)SkinPrepSystemfortransdermaldrugdel...manandChiefExecutiveOfficer,willpresentatthe13thAn...ponsoredbytheNewYorkSocietyofSecuritiesAnalysts,at...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development 5160 1VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development 5160 2Reportlinker Adds US Disposable Medical Supplies Market Report 5156 1Reportlinker Adds US Disposable Medical Supplies Market Report 5156 2Reportlinker Adds US Disposable Medical Supplies Market Report 5156 3Reportlinker Adds US Disposable Medical Supplies Market Report 5156 4Reportlinker Adds US Disposable Medical Supplies Market Report 5156 5Reportlinker Adds US Disposable Medical Supplies Market Report 5156 6Reportlinker Adds US Disposable Medical Supplies Market Report 5156 7Reportlinker Adds US Disposable Medical Supplies Market Report 5156 8Reportlinker Adds US Disposable Medical Supplies Market Report 5156 9Reportlinker Adds US Disposable Medical Supplies Market Report 5156 10Reportlinker Adds US Disposable Medical Supplies Market Report 5156 11Reportlinker Adds US Disposable Medical Supplies Market Report 5156 12Cortheras Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 5152 1Cortheras Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 5152 2Cortheras Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 5152 3
...SS WIRE)--May 25, 2007 - ARIAD,Pharmaceuticals, In...vestigators from leading cancer centers will prese...s of the Company,s novel mTOR,inhibitor, AP23573, ...linical Oncology (ASCO) in Chicago, Illinois, on S...e 2 trial of single-agent,AP23573 in patients with...
...SS WIRE)--May 24, 2007 - A new analysis,has found ...n ways,that inadvertently omit women and African-A...ty School of Medicine,researcher who led the effor...hat strict study eligibility criteria can have,uni... from a pool of 100,000 alcohol treatment,patients...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 2Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 3
(Date:11/24/2009)...to a significantly higher risk of strokes and card... in the British Medical Journal . , The researc...nization,s Collaborating Centre for Nutrition, bas...pital in Coventry, UK, and the European Society of...sed at the Department of Clinical and Experimental...
(Date:11/24/2009)...sity School of Medicine (BUSM) and the Boston Univ...tified a number of proteins whose activation allow...lls with almost 97 percent accuracy. In addition, ...nal strategy to analyze this data and specifically...its) that are active in cancer and "dormant" in no...
(Date:11/24/2009)...e/--TheBaylorCharlesA.SammonsCancerCenterhasbecome...operativegroupsintheUnitedStates.Fundedbyresearchg...ogyGroupconductsclinicaltrialstopreventandtreatcan...urvivors. ,, "Joiningthisprestigiousgroupwillal...ncerpatientsinNorthTexas,"saidAlanM.Miller,M.D.,Ph...
(Date:11/24/2009)...-USNewswire/--IPROhasachieveditsthirdconsecutiveIS...ndardfocusedonfulfillingcustomerrequirements,enhan...inessperformance.CertificationtoISO9001:2008bySGSI...yManagementSystem(QMS)haspassedarigorousexternalau...andAlbany,NewYorkaswellasatitsaffiliateLogiqual,LL...
(Date:11/24/2009)...use of inflammatory bowel disease is largely unkno... 2009 Advances in Inflammatory Bowel Diseases, the...inical & Research Conference, December 3-6 in ...mutation for Crohn’s disease. , ...9 -- The molecular cause of inflammatory bowel dis...
Breaking Medicine News(10 mins):Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2Health News:IPRO Earns Third Consecutive Quality Management Certification 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4
...cognition to encourage Americans to think, talk an..., WHITE PLAINS, N.Y., March 3 Today, the Dannon ...tivia featuring award-winning,actress and passiona...digestive health, sheds light on this,all-too-freq...
...ersal Pictures, Drama The Express Named National, ...s 2008 Light The Night ...n, who stars in the,upcoming drama The Express as ...for The Leukemia & Lymphoma Society,s,(LLS) 2008 L...
...3 The Providence Service,Corporation (Nasdaq: PR...t,financial results for its fourth quarter and yea...2008, after the market closes., Providence will h...rporate developments. Interested parties are,invit...
... CEL-SCI CORPORATION,(Amex: CVM ) provided detail... on groundbreaking activities currently underway a...and. The facility will be used,to manufacture Mult...nts. The facility, which is being built by the des...
...b Bridges Information Gap Between Clinics and ...rael, March 3 Orthocrat Ltd, a leading,provider o...ware, will,launch its unique Orthoweb on-line serv... step forward in bridging the workflow gap between...
...mmended by Annelies Boonen of Faculty of 1000 Medi...itis is diagnosed by analysing the administrative ...thors of the paper, published in Arthritis & Rheum...lf of these patients were seen in the first three ...
Other Medicine News:Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 2Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 3Health News:Actor Rob Brown Rushes to Gain Ground Against Blood Cancer 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial 2Health News:Orthocrat to Launch On-Line Service for Storing and Sharing Pre-Operative Data at AAOS 2
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: